These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 1874931)
1. Calcium supplementation reduces vertebral bone loss in perimenopausal women: a controlled trial in 248 women between 46 and 55 years of age. Elders PJ; Netelenbos JC; Lips P; van Ginkel FC; Khoe E; Leeuwenkamp OR; Hackeng WH; van der Stelt PF J Clin Endocrinol Metab; 1991 Sep; 73(3):533-40. PubMed ID: 1874931 [TBL] [Abstract][Full Text] [Related]
2. Long-term effect of calcium supplementation on bone loss in perimenopausal women. Elders PJ; Lips P; Netelenbos JC; van Ginkel FC; Khoe E; van der Vijgh WJ; van der Stelt PF J Bone Miner Res; 1994 Jul; 9(7):963-70. PubMed ID: 7942164 [TBL] [Abstract][Full Text] [Related]
3. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. Kung AW; Yeung SS J Clin Endocrinol Metab; 1996 Mar; 81(3):1232-6. PubMed ID: 8772604 [TBL] [Abstract][Full Text] [Related]
4. Effect of calcium supplementation on bone loss in postmenopausal women. Reid IR; Ames RW; Evans MC; Gamble GD; Sharpe SJ N Engl J Med; 1993 Feb; 328(7):460-4. PubMed ID: 8421475 [TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265 [TBL] [Abstract][Full Text] [Related]
6. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause. Gennari C; Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Bufalino L; Passeri M Menopause; 1998; 5(1):9-15. PubMed ID: 9689189 [TBL] [Abstract][Full Text] [Related]
7. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. Rosen CJ; Chesnut CH; Mallinak NJ J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404 [TBL] [Abstract][Full Text] [Related]
8. The effect of calcium supplements on plasma alkaline phosphatase and urinary hydroxyproline in postmenopausal women. Horowitz M; Need AG; Philcox JC; Nordin BE Horm Metab Res; 1985 Jun; 17(6):311-2. PubMed ID: 4018720 [TBL] [Abstract][Full Text] [Related]
9. Effect of a single infusion of aminohydroxypropylidene on calcium and bone metabolism in healthy volunteers monitored during 2 months. Netelenbos JC; van Ginkel FC; Lips P; Leeuwenkamp OR; Barto R; van der Vijgh WJ; van der Wiel H; Hackeng WH J Clin Endocrinol Metab; 1991 Jan; 72(1):223-8. PubMed ID: 1986022 [TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of calcium and estrogen administration on bone mass and metabolism after ovariectomy. Gambacciani M; Spinetti A; Taponeco F; Ciaponi M; Cima GP; Teti GC; Genazzani AR Gynecol Endocrinol; 1995 Jun; 9(2):131-5. PubMed ID: 7502689 [TBL] [Abstract][Full Text] [Related]
11. VDR genotype and response to etidronate therapy in late postmenopausal women. Marc J; Prezelj J; Komel R; Kocijancic A Osteoporos Int; 1999; 10(4):303-6. PubMed ID: 10692979 [TBL] [Abstract][Full Text] [Related]
12. [Serum osteocalcin in hyperthyroidism]. Roiter I; Legovini P; Da Rin G; Galliazzo S; Di Virgilio R; Foscolo G; Breda F; Conte N Ann Ital Med Int; 1990; 5(2):95-9. PubMed ID: 2248865 [TBL] [Abstract][Full Text] [Related]
13. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy? Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729 [TBL] [Abstract][Full Text] [Related]
14. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. Khan SA; Kanis JA; Vasikaran S; Kline WF; Matuszewski BK; McCloskey EV; Beneton MN; Gertz BJ; Sciberras DG; Holland SD; Orgee J; Coombes GM; Rogers SR; Porras AG J Bone Miner Res; 1997 Oct; 12(10):1700-7. PubMed ID: 9333131 [TBL] [Abstract][Full Text] [Related]
15. Common biochemical markers of bone turnover predict future bone loss: a 5-year follow-up study. Löfman O; Magnusson P; Toss G; Larsson L Clin Chim Acta; 2005 Jun; 356(1-2):67-75. PubMed ID: 15936304 [TBL] [Abstract][Full Text] [Related]
16. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473 [TBL] [Abstract][Full Text] [Related]
17. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss. Heikkinen JE; Selander KS; Laitinen K; Arnala I; Väänänen HK J Bone Miner Res; 1997 Jan; 12(1):103-10. PubMed ID: 9240732 [TBL] [Abstract][Full Text] [Related]
18. Biochemical effects of calcium supplementation in postmenopausal osteoporosis. Horowitz M; Need AG; Morris HA; Wishart J; Nordin BE Eur J Clin Nutr; 1988 Sep; 42(9):775-8. PubMed ID: 3181110 [TBL] [Abstract][Full Text] [Related]
19. Age and menopause-related changes in indices of bone turnover. Kelly PJ; Pocock NA; Sambrook PN; Eisman JA J Clin Endocrinol Metab; 1989 Dec; 69(6):1160-5. PubMed ID: 2511220 [TBL] [Abstract][Full Text] [Related]
20. Rectal salmon calcitonin for the treatment of postmenopausal osteoporosis. Overgaard K; Hansen MA; Dirksen KL; Christiansen C Calcif Tissue Int; 1992 Sep; 51(3):184-8. PubMed ID: 1422962 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]